Intact Vascular, Inc. Strengthens Executive Management Team Adding Bryan A. Claseman as VP of Marketing & Business Development and Marc Penna as VP of Clinical Affairs

NOVEMBER 3, 2014 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Bryan A. Claseman and Marc Penna have joined the Company as VP of Marketing & Business Development and VP of Clinical Affairs, respectively.

Intact Vascular CEO, Bruce Shook commented, “Bryan and Marc bring us depth of experience and a combination of marketing and clinical research skills that position us for great success as we move forward with the development of our Tack Endovascular SystemTM. We are all excited to have these talented executives join our team on the same day.”

Mr. Claseman joins the Company from Preventice, where he was VP Marketing. He brings over 30 years of medical device experience with a decade each in vascular, orthopedic, and urology markets. He has held senior management and executive marketing, business development, and information technology positions at several early stage companies including Cardiovascular Systems, Surmodics, and IntraTherapeutics, and several multi-national companies (Zimmer, Boston Scientific, Pfizer, Schneider Worldwide, American Medical Systems).

Bryan Claseman said, “I am excited to join Bruce and the executive management team at Intact Vascular. The Company has developed an innovative technology for the treatment of vascular dissections that complements all forms of balloon angioplasty and holds promise for advancing endovascular therapy throughout the periphery.”

Mr. Penna joins the Company from Angiodynamics where he was Senior Director of Clinical and Medical Affairs. He has more than 10 years of experience in the medical device industry managing all phases of clinical research including pre-clinical, pivotal and post-market clinical trials. He has held positions at Edwards Lifesciences where he managed large-scale transcatheter aortic valve replacement (TAVR) pivotal trials and at Boston Scientific where he worked on drug eluting stents. Mr. Penna has spent the majority of his career working in the cardiovascular, endovascular and oncology therapeutic areas.

Marc Penna commented, “Intact Vascular is addressing a key unmet need in endovascular therapy and I am thrilled to become part of the team that will drive this innovation forward. The Company has made a considerable investment in clinical research and I look forward to building upon that strong foundation.”

About Intact Vascular
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products, and is dedicated to improving the lives of patients who suffer from peripheral vascular disease. The Tack Endovascular

SystemTM is designed to optimize balloon angioplasty results in the treatment of peripheral artery disease. Visit for more information.

Intact Vascular
Andrea Dunkle, 484-253-1048

Scroll to Top
Intact Vascular uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this.